|

Anti-PD-L1 Monoclonal Antibody Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Envafolimab

Pipeline

Phase 2: 2

Top Sponsors

  • Yuanquan Yang1
  • Second Affiliated Hospital, School of Medicine, Zhejiang University1

Indications

  • Cancer2
  • Colon Neoplasm1
  • Hematopoietic and Lymphatic System Neoplasm1
  • Advanced Malignant Solid Neoplasm1

Other1 trial

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
Phase 2

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.